-+ 0.00%
-+ 0.00%
-+ 0.00%

AnaCardio raises €62.5 million in Series B co-led by Novo Holdings, Sound Bioventures joins investors

PUBT·09/30/2026 12:14:37
Listen to the news
AnaCardio raises €62.5 million in Series B co-led by Novo Holdings, Sound Bioventures joins investors
  • AnaCardio closed a EUR 62.5 million Series B round to fund late-stage development of its lead heart failure drug, AC01.
  • Sound Bioventures participated alongside co-leads Novo Holdings and the Ljungström family office, with Helsinn also investing.
  • Proceeds earmarked for the GOAL-HF2 Phase 2b trial, targeting Phase 3 readiness for AC01 by 2028.
  • AC01 is a first-in-class oral ghrelin receptor agonist aimed at improving cardiac contractility in advanced HFrEF without conventional inotrope safety risks.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sound Bioventures Management AB published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.